Although our previous study (Goldberg et al., 2012) with high doses of T3 and T2 was not meant to investigate their use as therapeutic agents, the elicited dramatic reduction in circulating cholesterol levels in hypercholesterolemic Ldlr−/− mice opened new perspectives in defining non-LDLr pathways that may have potential for the treatment of hypercholesterolemia. Here, LDLR is linked to familial hypercholesterolemia.